Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
World Journal of Surgical Oncology
January 2025

Prospective multicenter analysis shows the 31-gene expression profile test reduces unnecessary sentinel lymph node biopsies in melanoma patients

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World J Surg Onc. 23, 5 (2025). https://doi.org/10.1186/s12957-024-03640-x

‍

View PublicationResults
Introduction

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-SLNB) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.

Methods

The i31-SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322). To determine if incorporating the i31-SLNB into decision-making resulted in fewer SLNBs performed, propensity score-matching was performed to a non-overlapping cohort for whom the i31-SLNB was not used for SLNB decision-making.

Results

No patients with < 5% i31-SLNB predicted risk had a positive SLNB (0/35). Propensity matching demonstrated an 18.5% reduction in SLNBs performed (43.7% vs. 62.2%. p < 0.001). The i31-SLNB could have reduced the number of unnecessary biopsies by 25.0% (35/140).

Conclusion

This prospective study confirmed the performance and clinical utility of the i31-SLNB for improving risk-aligned care and demonstrated a significantly reduced SLNB performance rate when incorporating the i31-SLNB into clinical decision-making.

Want to learn more about
DecisionDx-Melanoma?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
World Journal of Surgical Oncology
January 2025

Prospective multicenter analysis shows the 31-gene expression profile test reduces unnecessary sentinel lymph node biopsies in melanoma patients

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World J Surg Onc. 23, 5 (2025). https://doi.org/10.1186/s12957-024-03640-x

‍

View PublicationResults
Introduction

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-SLNB) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.

Methods

The i31-SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322). To determine if incorporating the i31-SLNB into decision-making resulted in fewer SLNBs performed, propensity score-matching was performed to a non-overlapping cohort for whom the i31-SLNB was not used for SLNB decision-making.

Results

No patients with < 5% i31-SLNB predicted risk had a positive SLNB (0/35). Propensity matching demonstrated an 18.5% reduction in SLNBs performed (43.7% vs. 62.2%. p < 0.001). The i31-SLNB could have reduced the number of unnecessary biopsies by 25.0% (35/140).

Conclusion

This prospective study confirmed the performance and clinical utility of the i31-SLNB for improving risk-aligned care and demonstrated a significantly reduced SLNB performance rate when incorporating the i31-SLNB into clinical decision-making.

Want to learn more about
DecisionDx-SCC?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
World Journal of Surgical Oncology
January 2025

Prospective multicenter analysis shows the 31-gene expression profile test reduces unnecessary sentinel lymph node biopsies in melanoma patients

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World J Surg Onc. 23, 5 (2025). https://doi.org/10.1186/s12957-024-03640-x

‍

View PublicationResults
Introduction

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-SLNB) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.

Methods

The i31-SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322). To determine if incorporating the i31-SLNB into decision-making resulted in fewer SLNBs performed, propensity score-matching was performed to a non-overlapping cohort for whom the i31-SLNB was not used for SLNB decision-making.

Results

No patients with < 5% i31-SLNB predicted risk had a positive SLNB (0/35). Propensity matching demonstrated an 18.5% reduction in SLNBs performed (43.7% vs. 62.2%. p < 0.001). The i31-SLNB could have reduced the number of unnecessary biopsies by 25.0% (35/140).

Conclusion

This prospective study confirmed the performance and clinical utility of the i31-SLNB for improving risk-aligned care and demonstrated a significantly reduced SLNB performance rate when incorporating the i31-SLNB into clinical decision-making.

Want to learn more about
Mypath-Melanoma?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
World Journal of Surgical Oncology
January 2025

Prospective multicenter analysis shows the 31-gene expression profile test reduces unnecessary sentinel lymph node biopsies in melanoma patients

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World J Surg Onc. 23, 5 (2025). https://doi.org/10.1186/s12957-024-03640-x

‍

View PublicationResults
Introduction

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-SLNB) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.

Methods

The i31-SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322). To determine if incorporating the i31-SLNB into decision-making resulted in fewer SLNBs performed, propensity score-matching was performed to a non-overlapping cohort for whom the i31-SLNB was not used for SLNB decision-making.

Results

No patients with < 5% i31-SLNB predicted risk had a positive SLNB (0/35). Propensity matching demonstrated an 18.5% reduction in SLNBs performed (43.7% vs. 62.2%. p < 0.001). The i31-SLNB could have reduced the number of unnecessary biopsies by 25.0% (35/140).

Conclusion

This prospective study confirmed the performance and clinical utility of the i31-SLNB for improving risk-aligned care and demonstrated a significantly reduced SLNB performance rate when incorporating the i31-SLNB into clinical decision-making.

Would you like to talk more about
data related to TissueCypher?

Contact Us